A5000444179- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Glycosylation and Glycoproteins Research
- Estrogen and related hormone effects
- Retinoids in leukemia and cellular processes
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- RNA Interference and Gene Delivery
- Mycobacterium research and diagnosis
- Antioxidant Activity and Oxidative Stress
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Treatments and Studies
- Hematopoietic Stem Cell Transplantation
- Genetic factors in colorectal cancer
- Protein Degradation and Inhibitors
- Inflammatory mediators and NSAID effects
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Gastric Cancer Management and Outcomes
- Skin Protection and Aging
- Biotin and Related Studies
- Cancer Risks and Factors
- Sex and Gender in Healthcare
The University of Texas MD Anderson Cancer Center
2005-2023
University Hospital of Geneva
2012
Lymphoma Research Foundation
2002-2007
The University of Texas Health Science Center at Houston
1995
Abstract NeuVax is a vaccine comprised of the HER2-derived MHC class I peptide E75 (nelipepimut-S, NPS) combined with GM-CSF. We completed randomized trial preoperative vaccination versus GM-CSF alone in patients ductal carcinoma situ (DCIS). The primary objective was to evaluate for NPS-specific cytotoxic T lymphocyte (CTL) responses. Patients human leukocyte antigen (HLA)-A2-positive DCIS were enrolled and 2:1 received two inoculations prior surgery. number CTL measured pre-vaccination, at...
Successful therapeutic cancer prevention requires definition of the minimal effective dose. Aromatase inhibitors decrease breast incidence in high-risk women, but use and compliance adjuvant settings are hampered by adverse events.
Background. Using an a priori theoretic model of behavior change, factors predicting enrollment in randomized chemoprevention trial during the first year recruitment were assessed prospectively. Methods. Eligible participants asked to complete 90-item semistructured questionnaire after attendance at informational meeting. Components Health Belief Model (including perceived susceptibility, severity, benefits and barriers, cues action, health motivation), status, preventive behaviors, social...
Abstract Obesity, a cause of subclinical inflammation, is risk factor for the development postmenopausal breast cancer and associated with poorer outcomes. Docosahexaenoic acid (DHA), an omega-3 fatty acid, possesses anti-inflammatory properties. We hypothesized that treatment DHA would reduce expression proinflammatory genes aromatase, rate-limiting enzyme estrogen biosynthesis, in benign tissue overweight/obese women. A randomized, placebo-controlled, double-blind phase II study given 12...
Objective Lynch Syndrome (LS) carriers have a significantly increased risk of developing colorectal cancer (CRC) during their lifetimes. Further stratification this patient population may help in identifying additional factors that predispose to carcinogenesis. In most LS patients CRC arise from adenomas, although an alternative non-polypoid carcinogenesis pathway has been proposed for PMS2 carriers. Using data our institutional cohort, aim was describe current screening outcomes with focus...
<h3>Objective:</h3> We evaluated preoperative data that may predict benefit from secondary cytoreductive surgery (CRS) to assist in selecting therapy for patients with platinum-sensitive recurrent epithelial ovarian cancer. <h3>Materials and Methods:</h3> Inclusion criteria included or primary peritoneal carcinoma an initial disease-free interval more than 6 months after chemotherapy, evidence of disease on imaging studies indication being debulk residual disease. Preoperative CA125 values,...
Abstract Agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking. Rexinoids such as bexarotene significantly reduced mammary tumor development in preclinical mouse models. Oral BRCA mutation carriers decreased cyclin D1 cells, suggesting biological activity on tissue. This study evaluated topical 1% gel applied to one unaffected women at high risk for 4 weeks assess safety and toxicity. Secondary objectives included assessment concentrations...
<p>Supplementary Fig. S1: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving NeuVax with corresponding HER2 changes</p>
<p>Supplementary Fig. S2: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving GM-CSF alone with corresponding HER2 changes</p>
<p>Supplementary Fig. S2: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving GM-CSF alone with corresponding HER2 changes</p>
<p>Supplementary Fig. S1: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving NeuVax with corresponding HER2 changes</p>